MediWound Ltd. announced on April 28, 2025, that it would present 10 scientific abstracts, including oral and poster presentations, at the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025. These conferences took place from April 30 to May 3 in Grapevine, Texas.
The presentations featured new preclinical and clinical data on EscharEx, MediWound’s investigational enzymatic therapy for chronic wounds. The findings offered insights into EscharEx’s multitargeted and selective mechanism of action, reinforcing the ongoing VALUE Phase III study in venous leg ulcers (VLUs).
The data also supported the planned clinical trial strategy for diabetic foot ulcers (DFUs) and highlighted EscharEx's preclinical advantages over SANTYL. This scientific dissemination is crucial for validating the therapy's potential and informing the medical community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.